EE05331B1 - Bensamiididerivaati sisaldav farmatseutiline preparaat - Google Patents

Bensamiididerivaati sisaldav farmatseutiline preparaat

Info

Publication number
EE05331B1
EE05331B1 EEP200200073A EEP200200073A EE05331B1 EE 05331 B1 EE05331 B1 EE 05331B1 EE P200200073 A EEP200200073 A EE P200200073A EE P200200073 A EEP200200073 A EE P200200073A EE 05331 B1 EE05331 B1 EE 05331B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical preparation
preparation containing
benzamide derivative
benzamide
derivative
Prior art date
Application number
EEP200200073A
Other languages
English (en)
Inventor
Suzuki Tsuneji
Ando Tomoyuki
Ishibashi Masahiko
Sakabe Masahiro
Sakai Ikuo
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200200073A publication Critical patent/EE200200073A/et
Publication of EE05331B1 publication Critical patent/EE05331B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200073A 1999-08-16 2000-08-16 Bensamiididerivaati sisaldav farmatseutiline preparaat EE05331B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22955199A JP2001064177A (ja) 1999-08-16 1999-08-16 ベンズアミド誘導体を有効成分とする製剤
PCT/EP2000/008011 WO2001012193A1 (en) 1999-08-16 2000-08-16 Pharmaceutical agent comprising a benzamide derivative as active ingredient

Publications (2)

Publication Number Publication Date
EE200200073A EE200200073A (et) 2003-04-15
EE05331B1 true EE05331B1 (et) 2010-08-16

Family

ID=16893948

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200073A EE05331B1 (et) 1999-08-16 2000-08-16 Bensamiididerivaati sisaldav farmatseutiline preparaat

Country Status (29)

Country Link
EP (1) EP1207881B1 (et)
JP (2) JP2001064177A (et)
KR (1) KR100683876B1 (et)
CN (1) CN1205931C (et)
AR (1) AR031074A1 (et)
AU (1) AU780151B2 (et)
BG (1) BG65662B1 (et)
BR (1) BR0013283A (et)
CA (1) CA2380757C (et)
CY (1) CY1116273T1 (et)
CZ (1) CZ302924B6 (et)
DK (1) DK1207881T3 (et)
EE (1) EE05331B1 (et)
ES (1) ES2536705T3 (et)
HK (1) HK1046501B (et)
HR (1) HRP20020181B1 (et)
HU (1) HU230386B1 (et)
IL (1) IL148169A0 (et)
MX (1) MXPA02001575A (et)
NO (1) NO328957B1 (et)
NZ (1) NZ517356A (et)
PL (1) PL201388B1 (et)
PT (1) PT1207881E (et)
RU (1) RU2257206C2 (et)
SK (1) SK287547B6 (et)
TW (1) TWI245630B (et)
UA (1) UA73316C2 (et)
WO (1) WO2001012193A1 (et)
ZA (1) ZA200201466B (et)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
CA2423329A1 (en) * 2000-09-22 2003-03-20 Takeda Chemical Industries, Ltd. Solid preparations
WO2003075856A2 (en) 2002-03-07 2003-09-18 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
GB0316206D0 (en) 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
WO2008123395A1 (ja) 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
KR101405615B1 (ko) * 2007-08-27 2014-06-12 (주)아모레퍼시픽 조성물 내 ｐＨ 조절을 통해 안정화된 벤즈아미드 화합물을함유하는 피부 외용제 조성물, 및 그 벤즈아미드 화합물안정화 방법
PT2350005E (pt) * 2008-08-29 2012-03-12 Bayer Pharma AG Polimorfo b de n-(2-aminofenil)-4-[n-(piridina-3-il)¿ metoxicarbonil-aminometil]-benzamida (ms-275)
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
CN104334169B (zh) * 2013-04-04 2016-11-02 第一三共株式会社 包含氨基羧酸盐的固体组合物
US10561628B2 (en) 2015-03-19 2020-02-18 Daiichi Sankyo Company, Limited Solid preparation including antioxidant
BR112017019920B1 (pt) 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited Preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica
TWI845532B (zh) 2018-07-30 2024-06-21 日商第一三共股份有限公司 含安定劑之醫藥品的固體製劑
CN111867559A (zh) * 2019-01-25 2020-10-30 株式会社爱茉莉太平洋 含有苯甲酰胺化合物以及增溶剂的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer

Also Published As

Publication number Publication date
BG106516A (en) 2002-10-31
PT1207881E (pt) 2015-06-05
CY1116273T1 (el) 2017-02-08
NO20020774D0 (no) 2002-02-15
CZ302924B6 (cs) 2012-01-18
PL353449A1 (en) 2003-11-17
DK1207881T3 (da) 2015-06-22
IL148169A0 (en) 2002-09-12
NO20020774L (no) 2002-03-04
AU6442700A (en) 2001-03-13
HUP0203226A3 (en) 2003-12-29
CN1205931C (zh) 2005-06-15
BR0013283A (pt) 2002-04-23
AU780151B2 (en) 2005-03-03
TWI245630B (en) 2005-12-21
WO2001012193A1 (en) 2001-02-22
BG65662B1 (bg) 2009-05-29
NZ517356A (en) 2003-07-25
ZA200201466B (en) 2002-09-02
KR100683876B1 (ko) 2007-02-15
JP2001064177A (ja) 2001-03-13
CA2380757A1 (en) 2001-02-22
JP4854158B2 (ja) 2012-01-18
MXPA02001575A (es) 2003-10-14
EE200200073A (et) 2003-04-15
AR031074A1 (es) 2003-09-10
HK1046501B (zh) 2005-09-30
RU2002106815A (ru) 2004-01-27
KR20020020815A (ko) 2002-03-15
ES2536705T3 (es) 2015-05-27
SK2092002A3 (en) 2002-07-02
EP1207881B1 (en) 2015-04-01
EP1207881A1 (en) 2002-05-29
CN1370068A (zh) 2002-09-18
HRP20020181B1 (hr) 2016-01-29
CZ2002540A3 (cs) 2002-06-12
HRP20020181A2 (en) 2005-10-31
SK287547B6 (sk) 2011-01-04
HK1046501A1 (en) 2003-01-17
RU2257206C2 (ru) 2005-07-27
HUP0203226A2 (hu) 2003-01-28
UA73316C2 (uk) 2005-07-15
HU230386B1 (hu) 2016-03-29
PL201388B1 (pl) 2009-04-30
CA2380757C (en) 2009-01-27
NO328957B1 (no) 2010-06-28
JP2003507330A (ja) 2003-02-25

Similar Documents

Publication Publication Date Title
EE05063B1 (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
DK1207868T3 (da) Farmaceutiske tramadolsalte
PT984773E (pt) Formulacao farmaceutica a base de omeprazole
ITMI20001450A0 (it) Nuova composizione farmaceutica
NO20005218L (no) Farmasöytisk aerosolpreparat
DK1466615T3 (da) Farmaceutisk præparat
NO20015149L (no) Nytt farmasöytisk preparat
NO20015670L (no) Forbedrede farmasöytiske formuleringer
NO20022606L (no) Farmasöytiske kombinasjoner
EE05331B1 (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
NO20014926D0 (no) Farmasöytiske forbindelser
NO20015148D0 (no) Nytt farmasöytisk preparat
EE9900545A (et) Farmatseutiline kompositsioon
DK1227817T3 (da) Ciclesonid-holdigt vandigt farmaceutisk præparat
FI4488U1 (fi) Farmaseuttinen koostumus
NO20015104L (no) Nytt farmasöytisk preparat
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20016430D0 (no) Farmasöytisk kompleks
NO20015105D0 (no) Nytt farmasöytisk preparat
NO20021036D0 (no) Farmasöytisk preparat
SE9904819D0 (sv) A new pharmaceutical composition
SE9800251D0 (sv) A novel pharmaceutical preparation
DK1060749T3 (da) Vandigt farmaceutisk præparat indeholdende Tezosentan
DE50008261D1 (de) Retardierte darreichungsform enthaltend tramadolsaccharinat

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner